Replies to post #162973 on Cytodyn Inc (CYDY)

[MFGinvestor]

https://www.nejm.org/doi/full/10.1056/nejmoa1711460

[MFGinvestor]

https://www.fda.gov/news-events/press-announcements/fda-approves-new-hiv-treatment-patients-who-have-limited-treatment-options

[ClosetInvestor]

“Ibalizumab was approved with 40 patients and 43% efficacy in 25 weeks study IV Infusion ..with some side effects ..
one or two years ago.”

True, but ibalizumab had already completed a phase 2 with 113 patients AND had a concurrent phase 3 with another 78 patients. Additionally, the ibalizumab phase 3 study was published in the NJEM.

Full data from the combo trial, CD02, has never been released, which it should have been by now considering the trial completed in 2018.